Inhibitors such as pembrolizumab and nivolumab (targeting PD-1), and atezolizumab (targeting PD-L1) block these interactions, restoring T-cell activity and enabling a more robust response against the tumor. 10. This evidence concerns the gene CD274 and neoplasm.